SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending as the community discusses recent developments including Gravity SUV deliveries in Canada and a partnership with Riyadh Season. Despite positive news, concerns persist around production targets, potential dilution, and the company's overall financial health, fueling debate among investors. Some are optimistic about Lucid's technology and long-term potential, while others express skepticism about its ability to compete effectively in the EV market.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine ($APPS) is trending as investors discuss its potential in the evolving app store landscape following recent rulings and potential AI partnerships; the community is actively debating whether the stock's current momentum is sustainable and if it can maintain its upward trajectory, with some closely watching for a breakout while short positions may get squeezed. Broader discussions cover the company's restructuring, potential acquisitions, and impact of broader market trends.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X ($CCCX) is trending as the quantum computing sector gains momentum, with community members highlighting its undervaluation compared to peers like $RGTI and potential links to $NVDA. Discussions revolve around the upcoming merger with Infleqtion and its participation in the Q+AI Conference 2025 as potential catalysts. Some investors express excitement about the stock's long-term potential, drawing parallels to past SPAC successes.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

ARTV is trending due to positive sentiment around potential upgrades and community excitement about its gains, with some eyeing a move to double digits. Bullish traders are celebrating recent wins and expressing confidence in the stock's undervaluation, citing Wedbush's price target. However, some caution exists regarding potential pullbacks, with a few traders closing positions for profit.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending due to a mix of factors, including recent price volatility and discussions around a potential CEO share sale. The community is debating potential support levels and whether the stock is currently oversold, while also considering the company's broader positioning in the telehealth and pharmaceutical landscape.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Amstelveen, Netherlands.

ATAI Life Sciences N.V.

ATAI is trending after receiving FDA Breakthrough Therapy Designation for its depression treatment, BPL-003, driving excitement among investors. Community members are discussing Jefferies' raised price target to $10 and the potential for Phase 3 trials, while also weighing the impact of a recent public offering.  The stock is viewed by some as a long-term play in the burgeoning psychedelic medicine sector, drawing comparisons to $TSLA and $NVDA.

Firecoin is a digital asset inspired by the concept of the eternal flame, representing energy, resilience, and guidance. It is designed to act as a decentralized token that embodies light and strength, giving holders a sense of empowerment in the digital economy. The project’s purpose is to create a community-driven ecosystem where Firecoin symbolizes progress, illumination, and the ability to move forward regardless of challenges. By leveraging blockchain technology, Firecoin aims to provide transparency, security, and accessibility to its users while maintaining its thematic connection to the symbolic power of fire.

firecoin

$FIRECOIN is trending due to increasing attention within the Phantom Wallet community, with many users highlighting its potential for significant gains. The community is actively discussing its availability on Phantom Wallet and anticipating a potential 'moonshot,' while some users are raising concerns about potential scams.

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Mind Medicine Inc

Mind Medicine Inc - Ordinary Shares (Sub Voting)

MNMD is trending as the community discusses potential catalysts, including positive trial data and regulatory developments in the psychedelics sector.  Bullish sentiment is fueled by the anticipation of significant price appreciation and potential buyouts, with the company's strong cash position and ongoing Phase 3 trials cited as key factors. Discussions also involve the broader context of psychedelic medicine's growing acceptance and potential to revolutionize mental health treatment.

VisionWave Holdings, Inc. engages in the forefront of revolutionizing defense capabilities by integrating advanced artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. The company was founded on September 3, 2024 and is headquartered in Wilmington, DE.

VisionWave Holdings Inc.

VisionWave Holdings, Inc.

VisionWave Holdings is trending due to upcoming live-fire trials in the UAE and discussions for strategic opportunities in Indian defense modernization programs, generating excitement around potential contracts. Community members are closely watching key resistance levels, particularly a break above $12.50, and discussing the warrants, viewing the company as undervalued in the AI and defense sector.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

ORCL is trending due to a mixed reaction to its AI World event and announcements, including a partnership with Meta and ambitious long-term revenue targets. While some analysts are optimistic, concerns linger in the community about near-term profitability, heavy AI capex, and execution risks. Community members are actively discussing potential price movements, upgrades from analysts, and the impact of AI deals on Oracle's future.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last?

Personalis (PSNL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Shares of Taysha Gene Therapies ended at their highest level in over three years on Thursday after a wave of bullish analyst upgrades followed the U.S. Food and Drug Administration’s (FDA) Breakthrough Therapy designation for its Rett syndrome gene therapy candidate, TSHA-102.The stock soared 53.5% on Thursday, extending gains by another 2% in after-hours trading.Baird raised its price target on Taysha to $12 from $7 and reiterated an 'Outperform' rating. Analyst Jack Allen said the firm is “encouraged” that Taysha reached alignment with the FDA on the 15-patient pivotal study for TSHA-102, calling the breakthrough therapy designation “another encouraging sign” for the company’s regulatory and clinical progress.H.C. Wainwright said Taysha has added roughly $1.2 billion to its valuation since receiving Breakthrough Therapy designation and aligning with the FDA on a six-month interim Biologics License Application (BLA) filing plan.&nbsp;The firm noted that while the accelerated pathway appears faster “on paper,” Rett specialists it surveyed said the six-month interim analysis was “directionally useful but insufficient on its own to be considered definitive for projecting patient outcomes.”&nbsp;The analysts added that Taysha’s pathway “looks faster on paper, but may not translate into a true lead.” In comparison, the firm said Neurogene, whose FDA-cleared 12-month design “mitigates the risk of approvability,” looks “deeply undervalued.” H.C. Wainwright reiterated its Buy rating and $45 price target on Neurogene, citing its durability focus and caregiver appeal.Needham analyst Gil Blum also raised the price target on Taysha to $10 from $8, keeping a 'Buy' rating. Blum told investors that the FDA’s feedback on Taysha’s registrational study design “checked off a wishlist of features,” including the agency’s willingness to allow for a six-month interim filing. The analyst said these developments “derisk” the TSHA-102 program and position it “well ahead of NGNE-401.”The FDA’s Breakthrough Therapy designation was based on data from 12 patients in an early-to mid-stage trial of TSHA-102 and allows for an expedited review process.&nbsp;Taysha has finalized alignment with the agency on the design of its registrational study, which will test a single intrathecal administration of high-dose TSHA-102 in 15 female patients aged 6 to under 22 years. The company plans to begin enrollment in the fourth quarter of 2025.On Stocktwits, retail sentiment for Taysha was ‘extremely bullish’ amid a 34,800% surge in 24-hour message volume.One retail trader said they expect institutional investors to accumulate Taysha shares around the $5 mark, predicting a quick move toward $6.&nbsp;<stembedurl>https://stocktwits.com/warren5677/message/630844528</stembedurl>Another user said they had exited their position at $4.85, citing the company’s high debt levels and booking an 8% profit.<stembedurl>https://stocktwits.com/intrader/message/630837982</stembedurl><a href="https://stocktwits.com/symbol/TSHA">Taysha’s stock</a> has nearly tripled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Taysha’s stock (TSHA) has nearly tripled so far in 2025. (Photo credit: Getty Images)

Taysha Gene Therapies Stock Soars To 3-Year High After FDA Boost — Wall Street Calls Rett Drug ‘Derisked’ And Ahead Of Rivals

Taysha shares jumped after analysts at Baird, H.C. Wainwright, and Needham turned bullish, citing FDA alignment and an expedited approval path for its Rett syndrome therapy.

Equity

Shares of Taysha Gene Therapies, Inc. (TSHA) rallied 49% by Thursday morning after the U.S. Food and Drug Administration granted Breakthrough Therapy designation to its gene therapy TSHA-102 for the treatment of Rett syndrome.Rett syndrome is a rare genetic neurological and developmental disorder that affects the way the brain develops. The disorder, which primarily occurs in females, is characterized by loss of communication and hand function, slowing and/or regression of development, motor and respiratory impairment, seizures, intellectual disabilities, and shortened life expectancy.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-fda-breakthrough-therapy">According</a> to Taysha, there are currently no approved disease-modifying therapies that treat the genetic root cause of the disease, which affects between 15,000 and 20,000 patients in the U.S., the EU, and the U.K.The FDA on Thursday granted Taysha’s TSHA-102 Breakthrough Therapy designation. It is intended to expedite the development and regulatory review of an investigational therapy intended to treat a serious condition. The designation follows the agency’s review of available clinical data from the 12 patients treated in a part of its early-to mid-stage trials.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TSHA">TSHA stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:573/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_11_39_41_AM_png_8ca9f60f70.webp" alt="TSHA's Sentiment Meter and Message Volume as of 11:39 a.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="573" height="63"><figcaption>TSHA's Sentiment Meter and Message Volume as of 11:39 a.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>Taysha also said on Thursday that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102. The company is now on track to begin patient enrollment in the trial in the fourth quarter of 2025. In the trial, a single intrathecal administration of high-dose TSHA-102 will be evaluated in 15 females between the ages of six and below 22 years with Rett syndrome.Following the news, Needham analyst Gil Blum raised the firm's price target on Taysha Gene Therapies to $10 from $8 while keeping a ‘Buy’ rating on the shares. Needham views the developments as "derisking" for TSHA-102, putting the program well ahead of Neurogene’s gene therapy NGN-401, which is also being evaluated for Rett syndrome.TSHA stock has risen 174% this year and by about 131% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reports-7-percent-rise-in-q3-deliveries/chCrXlDR3Ow">Tesla’s Q3 Deliveries Hit Quarterly Record, Rise 7% To Exceed Analyst Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Taysha Gene Therapies Stock Soars After FDA Grants Breakthrough Therapy Designation To Gene Therapy

Taysha also announced that it has finalized alignment with the FDA on the protocol for the trial intended to support its application for approval of TSHA-102.

Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Beats Revenue Estimates

Taysha Gene Therapies (TSHA) delivered earnings and revenue surprises of -28.57% and +15.73%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates

Amphastar (AMPH) delivered earnings and revenue surprises of +19.72% and +2.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade

Taysha Gene Therapies (TSHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?

Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Retail buzz around Taysha Gene Therapies Inc surged Tuesday after the company released new clinical results from its TSHA-102 trial for Rett syndrome.Taysha Gene Therapies shares dipped 0.2% to close at $2.78 on Tuesday, before gaining 0.7% to $2.8 in after-hours trading.During its Reveal Phase 1/2 trials, the company presented recent cohort data for TSHA-102, which administered high and low doses to adolescent,&nbsp;adult, and pediatric patients&nbsp;through lumbar intrathecal delivery.Caregiver-reported improvements in developmental milestones supported Taysha’s alignment with the U.S. Food and Drug Administration (FDA) on the primary endpoint for the pivotal Part B trial of TSHA-102.Previously released preclinical data demonstrated broad biodistribution of AAV9 gene therapy vectors across brain and spinal cord regions in non-human primates.Taysha will present these findings in three oral presentations and a poster session at the 2025 International Rett Syndrome Foundation (IRSF) Scientific Meeting in Boston, June 9-11.Canaccord Genuity raised its price target on Taysha shares to $11 from $9, while maintaining a ‘Buy’ rating, citing positive longer-term low-dose follow-up and initial high-dose data disclosed by the company.&nbsp;The research firm also increased its assigned probability of success (POS) for TSHA-102 to 75% from 50%.Canaccord’s updated model also factored in the recently announced approximately $200 million offering via a combination of shares and prefunded warrants.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘high’ message volume.One user noted that it is unusual for a stock to increase during an offering, welcoming Taysha as an exception.&nbsp;<stembedurl>https://stocktwits.com/KING_OF_BIO/message/616691905</stembedurl>Another user highlighted that all price targets for Taysha have been raised.<stembedurl>https://stocktwits.com/strategicmind/message/616553737</stembedurl>The stock has risen 50.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Buzz Surges Around Taysha Gene Therapies After Positive Rett Syndrome Trial Data

Canaccord Genuity raised its price target on Taysha Gene Therapies to $11 from $9, citing improved clinical data and increased confidence in the company’s TSHA-102 program. 

Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Taysha Gene Therapies Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

TSHA
Taysha Gene Therapies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TSHA News

TSHATaysha Gene Therapies Inc